Document is current
Any future updates will be listed below
-
Authors
Longobardi, Giuseppe
Shekhter, Pini
Conte, Claudia
Satchi-Fainaro, Ronit
Quaglia, Fabiana
-
Funding
Funding for this research was provided by:
European Research Council (ERC Advanced Grant 835227-3)
Israel Science Foundation (3706/24)
Israel Cancer Research Fund (Prof.-18-682)
Morris Kahn Foundation
National Center for Gene Therapy and Drugs Based on RNA Technology (CN00000041)
Tel Aviv University
- License Information
-
More Information
Article History
Received: 16 February 2026
Accepted: 30 March 2026
First Online: 8 May 2026
Declarations
:
: R.S.-F. is a board director at Teva Pharmaceutical Industries Ltd. and receives unrelated research funding from Merck KGaA. R.S.-F. is a cofounder and officer with an equity interest in Selectin Therapeutics Inc., and in ImmuNovation Tx Ltd. All other authors declare no conflict of interest.
